Clinical Trials

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07198074 2026-06-05

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT06952504 2026-06-03

TroFuse-033

1,123 enrolled

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07564141 2026-06-03

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04269200 2026-06-01

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT07216703 2026-06-01

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT01081262 2026-05-29

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01167712 2026-05-29

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT07213804 2026-05-27

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06989112 2026-05-06

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03556839 2026-04-21

BEATcc

410 enrolled

Carcinoma, Uterine Cervical Neoplasms

NCT07168200 2026-04-15

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

720 enrolled

Advanced Cervical Cancer

NCT04498117 2026-04-01

FLORA-5

615 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03884101 2026-02-02

LEAP-001

842 enrolled 25 charts

Endometrial Neoplasms

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06476184 2025-12-05

SALVOVAR

250 enrolled

Ovarian Neoplasms

NCT04865289 2025-12-02

LEAP-001

130 enrolled 24 charts

Endometrial Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

445 enrolled

Uterine Cervical Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

Phase 3 Withdrawn

Phase 3 Not yet recruiting

Uterine Cervical Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

50 enrolled

Stage III and IV Ovarian Cancer

NCT03603184 2025-05-09

AtTEnd

549 enrolled

Neoplasms, Endometrial Neoplasms

NCT05179239 2025-04-15

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated

31 enrolled

Uterine Cervical Neoplasms

NCT05737303 2025-02-11

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

538 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01566240 2024-12-05

INTERLACE

500 enrolled

Uterine Cervical Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

306 enrolled

Uterine Cervical Neoplasms

NCT02470585 2024-10-26

VELIA

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

NCT03635489 2024-10-03

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

100 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT03830866 2024-07-26

CALLA

770 enrolled 12 charts

Locally Advanced Cervical Cancer

NCT02501954 2024-07-23

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

48 enrolled

Endometrial Clear Cell Adenocarcinoma

NCT01820858 2024-04-02

EC-01

300 enrolled

Endometrial Neoplasms

NCT00657878 2023-11-13

MITO-8

215 enrolled

Ovarian Neoplasms

NCT02584478 2023-11-08

AL3818

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00411138 2023-10-11

PORTEC-3

670 enrolled

Endometrial Neoplasms

NCT03534713 2023-09-21

ONCOCOL01

310 enrolled

Uterine Cervical Neoplasms

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT02429687 2023-04-25

MOGCT-01

129 enrolled

Ovarian Germ Cell Cancer, Ovarian Neoplasms

NCT02429700 2023-04-25

SCST-01

132 enrolled